Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma.
Salvatori
Massimo
M
Nuclear Medicine Institute, Policlinico Universitario A.Gemelli, Catholic University of Sacred Heart, Rome, Italy. msalvatori@rm.unicatt.it
Luster
Markus
M
D018263:Adenocarcinoma, Follicular / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D002291:Carcinoma, Papillary / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D006980:Hyperthyroidism / Q000532:radiotherapy; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D049268:Positron-Emission Tomography; D011874:Radiometry / Q000379:methods*; D019275:Radiopharmaceuticals / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D013959:Thyroid Diseases / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging / Q000532:radiotherapy*; D013972:Thyrotropin / Q000494:pharmacology / Q000627:therapeutic use
D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals; D011994:Recombinant Proteins; D013972:Thyrotropin